Physician profile
Kelsey E Vukic
NPI 1972348126
$2,532.47
in general payments reported to CMS, 2019-2025
20 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,071 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,375 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.47 |
| Education | $157.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $361.48 | 2024-2025 | Gemtesa, Orgovyx |
| Endo USA, INC. | $324.52 | 2024-2025 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $250.98 | 2024-2025 | Erleada |
| Verity Pharmaceuticals INC. | $206.16 | 2024-2025 | Trelstar |
| Astellas Pharma US INC | $184.24 | 2024 | Xtandi |
| Tolmar, INC. | $163.02 | 2024-2025 | Jatenzo, Eligard |
| Dendreon Pharmaceuticals LLC | $150.79 | 2024-2025 | Provenge |
| Ferring Pharmaceuticals INC. | $148.23 | 2024-2025 | Adstiladrin |
| Pfizer INC. | $128.22 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $119.42 | 2024-2025 | |
| Boston Scientific Corporation | $102.78 | 2025 | Axonics |
| Merck Sharp & Dohme LLC | $85.56 | 2024-2025 | Keytruda |
| Antares Pharma, INC. | $71.45 | 2025 | Xyosted |
| Olympus America INC. | $63.56 | 2024-2025 | Itind System, Olympus |
| Astrazeneca Pharmaceuticals LP | $51.67 | 2024-2025 | Lynparza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $44.16 | 2025 | |
| Azurity Pharmaceuticals, INC. | $20.71 | 2025 | Azmiro |
| Myriad Genetic Laboratories, INC. | $20.62 | 2024 | Prolaris |
| Urogen Pharma, INC. | $18.95 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.95 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Vukic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.